NCT04210219 - A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

May 28, 2025

Study Completion Date

May 28, 2025

Conditions

Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG

JNJ-64264681

JNJ-64264681 capsule will be administered orally.

Trial Locations (15)

10029

Icahn School of Medicine at Mount Sinai, New York

10048

National Taiwan University Hospital, Taipei

40402

China Medical University Hospital, Taichung

40705

Taichung Veterans General Hospital, Taichung

70403

National Cheng Kung University Hospital, Tainan City

83301

Chang-Gung Memorial Hospital, Kaohsiung, Kaohsiung County

0112

Arensia Exploratory Medicine, Tbilisi

MD-2025

Arensia Exploratory Medicine, Chisinau

80 214

Uniwersyteckie Centrum Kliniczne, Gdansk

40 519

Pratia Onkologia Katowice, Katowice

30-727

Pratia MCM Krakow, Krakow

60 185

Centrum Medyczne Pratia Poznan, Skorzewo

01135

Medical Center of Limited Liability Company Arensia Exploratory Medicine, Kyiv

EC1M 6BQ

Queen Mary University of London, Charterhouse Square

PL6 8DH

Plymouth Hospitals NHS Trust, Plymouth

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY